Hangzhou Jitai Pharmaceutical Technology

Hangzhou Jitai Pharmaceutical Technology is a clinical-stage biotechnology company focused on the discovery and development of innovative small molecule drugs for metabolic diseases, including type 2 diabetes, obesity, and NASH. Utilizing an integrated AI-driven drug discovery platform and structure-based drug design, the company specializes in creating oral alternatives to traditional peptide-based injectable therapies. Its lead candidate, JT001, is a potent oral GLP-1 receptor agonist currently undergoing clinical evaluation. The company's pipeline also includes multi-target agonists such as GLP-1R/GIPR dual agonists and triple agonists. Headquartered in Hangzhou, China, Jitai Pharmaceutical aims to address significant unmet medical needs in the global metabolic health market.